BLeeding Events and Maintenance DoSe of PraSugrel

Inclusion Criteria: * all ACS patients treated with PCI (percutaneous coronary intervention) and dual antiplatelet therapy (DAPT: aspirin plus prasugrel). * Informed written consent Exclusion Criteria: * Age \< 18 years * Active bleeding; bleeding diathesis; coagulopathy * History of gastrointestinal or genitourinary bleeding \<2 months * Major surgery in the last 6 weeks * History of intracranial bleeding or structural abnormalities * Suspected aortic dissection * Any previous TIA (transient ischemic attack)/stroke * Administration in the week before the index event of clopidogrel, ticlopidine, prasugrel, ticagrelor, thrombolytics, bivalirudin, low-molecular weight heparin or fondaparinux . * Known relevant hematological deviations: Hb \<10 g/dl, Thrombocytopenia. \<100x10\^9/l * Use of coumadin derivatives within the last 7 days * Chronic therapy with prasugrel or ticagrelor * Known malignancies or other comorbid conditions with life expectancy \<1 year * Known severe liver disease, severe renal failure * Known allergy to the study medications * Pregnancy